News
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025 EBX-102 was well tolerated and showed multiple positive trends over placeboFindings support progression to a Phase 2b trial Glasgow, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback